Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions
Epithelial Ovarian Cancer
Interventions
BEHAVIORAL

Intermittent Fasting

Intermittent fasting (IF) also known as time restricted eating regimen consisting of 16 hours of fasting and 8 hours of ad libitum feeding for 5 days followed by ad libitum feeding for 2 days has been proposed. With this type of intervention, there are no dietary restrictions to the type or quality of food and it decreased daily energy intake by 20%. Participants will be asked to follow an IF schedule consisting of 16 hour of continuous fasting per day for 5 days a week. This will be started 2 days prior to chemotherapy (cycle 2).

DRUG

Neoadjuvant chemotherapy

Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.

Trial Locations (1)

44195

RECRUITING

Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER